Argo Biopharmaceutical Co Ltd, a China-based, clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Wednesday that it has been selected as a late breaking abstract to present Phase II interim data for BW-20805 during the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting.

BW-20805 is an investigational siRNA therapy that targets and significantly inhibits prekallikrein (PKK), a well-validated target for hereditary angioedema (HAE) treatment, offering the possibility of prevention of HAE attacks with a long-term effect.

The open-label study results, selected as a late breaking abstract presentation, titled 'Significant HAE Attack Reduction with BW-20805, a Long-Acting Prophylactic Injection-An Ongoing Phase 2 Study in Adults with Hereditary Angioedema' (POSTER ID: L42), show that BW-20805 provides plasma PKK reduction and time-normalised HAE attack rate reduction. The sustained PKK suppression and the favourable safety and tolerability profile support further evaluation of a Q6M dosing regimen.